Stamford Hospital to participate in US FDA Expanded Access Treatment IND program for Generex Oral-lyn

Published on February 24, 2011 at 3:50 AM · No Comments

Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board: GNBT) announced today that Stamford Hospital has agreed to participate in the United States Food and Drug Administration (FDA) Expanded Access Treatment Investigational New Drug (IND) Program for Generex Oral-lyn™, the Company's proprietary buccal insulin spray product for the treatment of patients with diabetes.

Stamford Hospital (www.stamfordhospital.org) is a not-for-profit provider of comprehensive healthcare services in Connecticut.  The mission of Stamford Hospital is to provide, together with its physicians, a broad range of high quality health and wellness services focused on the needs of the communities it serves.  Stamford Hospital is a member of the Planetree Alliance, a group of hospitals nationwide focused on patient-centered care.  Stamford Hospital is affiliated with the New York Presbyterian Health System and is a major teaching affiliate of the Columbia University College of Physicians and Surgeons.

Read in | English | Español | 日本語 | 한국어 | 简体中文 | Svenska
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post